JP2022512372A - ヒトおよび動物における「プラークおよびタングル」の処置のための組成物および方法 - Google Patents
ヒトおよび動物における「プラークおよびタングル」の処置のための組成物および方法 Download PDFInfo
- Publication number
- JP2022512372A JP2022512372A JP2021533339A JP2021533339A JP2022512372A JP 2022512372 A JP2022512372 A JP 2022512372A JP 2021533339 A JP2021533339 A JP 2021533339A JP 2021533339 A JP2021533339 A JP 2021533339A JP 2022512372 A JP2022512372 A JP 2022512372A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- extract
- disease
- composition according
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 380
- 238000000034 method Methods 0.000 title claims abstract description 109
- 238000011282 treatment Methods 0.000 title claims description 38
- 241001465754 Metazoa Species 0.000 title description 10
- 239000000284 extract Substances 0.000 claims abstract description 321
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 147
- 235000020333 oolong tea Nutrition 0.000 claims abstract description 146
- 235000001466 Ribes nigrum Nutrition 0.000 claims abstract description 129
- 235000016954 Ribes hudsonianum Nutrition 0.000 claims abstract description 125
- 240000001890 Ribes hudsonianum Species 0.000 claims abstract description 123
- 210000004556 brain Anatomy 0.000 claims abstract description 82
- 241001498622 Cixius wagneri Species 0.000 claims abstract description 64
- 108010026424 tau Proteins Proteins 0.000 claims description 105
- 102000013498 tau Proteins Human genes 0.000 claims description 105
- 206010002022 amyloidosis Diseases 0.000 claims description 65
- 230000015572 biosynthetic process Effects 0.000 claims description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- 208000024827 Alzheimer disease Diseases 0.000 claims description 49
- 208000010877 cognitive disease Diseases 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 46
- 238000009825 accumulation Methods 0.000 claims description 43
- 230000035508 accumulation Effects 0.000 claims description 42
- 206010012289 Dementia Diseases 0.000 claims description 40
- 229930002877 anthocyanin Natural products 0.000 claims description 38
- 235000010208 anthocyanin Nutrition 0.000 claims description 38
- 239000004410 anthocyanin Substances 0.000 claims description 38
- 150000004636 anthocyanins Chemical class 0.000 claims description 38
- 208000017004 dementia pugilistica Diseases 0.000 claims description 35
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 33
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 33
- 241000282472 Canis lupus familiaris Species 0.000 claims description 31
- 239000002775 capsule Substances 0.000 claims description 31
- 230000009529 traumatic brain injury Effects 0.000 claims description 31
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 30
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 30
- 230000008021 deposition Effects 0.000 claims description 29
- 230000002688 persistence Effects 0.000 claims description 28
- 208000034799 Tauopathies Diseases 0.000 claims description 26
- 229930014669 anthocyanidin Natural products 0.000 claims description 26
- 235000008758 anthocyanidins Nutrition 0.000 claims description 26
- 229920002770 condensed tannin Polymers 0.000 claims description 26
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 claims description 26
- 241000282326 Felis catus Species 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 22
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 20
- 235000013361 beverage Nutrition 0.000 claims description 19
- 230000019771 cognition Effects 0.000 claims description 18
- 102000001049 Amyloid Human genes 0.000 claims description 16
- 108010094108 Amyloid Proteins 0.000 claims description 16
- 244000269722 Thea sinensis Species 0.000 claims description 16
- 230000015654 memory Effects 0.000 claims description 16
- 208000011580 syndromic disease Diseases 0.000 claims description 16
- 235000013616 tea Nutrition 0.000 claims description 15
- 230000006999 cognitive decline Effects 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 230000009514 concussion Effects 0.000 claims description 13
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 12
- 208000024777 Prion disease Diseases 0.000 claims description 10
- 230000032683 aging Effects 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 241000282465 Canis Species 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 230000002490 cerebral effect Effects 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 230000001054 cortical effect Effects 0.000 claims description 8
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 7
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 7
- 208000005400 Synovial Cyst Diseases 0.000 claims description 7
- 230000007850 degeneration Effects 0.000 claims description 7
- 206010027175 memory impairment Diseases 0.000 claims description 7
- 239000000829 suppository Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000007903 gelatin capsule Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 201000010374 Down Syndrome Diseases 0.000 claims description 5
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 5
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 206010044688 Trisomy 21 Diseases 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 208000037976 chronic inflammation Diseases 0.000 claims description 5
- 230000006020 chronic inflammation Effects 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 208000014644 Brain disease Diseases 0.000 claims description 4
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 4
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000007894 caplet Substances 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000003930 cognitive ability Effects 0.000 claims description 4
- 238000005538 encapsulation Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 201000010901 lateral sclerosis Diseases 0.000 claims description 4
- 230000013016 learning Effects 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 230000003387 muscular Effects 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims description 4
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 3
- 208000032274 Encephalopathy Diseases 0.000 claims description 3
- 206010016202 Familial Amyloidosis Diseases 0.000 claims description 3
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 claims description 3
- 241001180747 Hottea Species 0.000 claims description 3
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 3
- 206010034010 Parkinsonism Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 3
- 206010044565 Tremor Diseases 0.000 claims description 3
- 230000037147 athletic performance Effects 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 210000003478 temporal lobe Anatomy 0.000 claims description 3
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 208000007650 Meningeal Carcinomatosis Diseases 0.000 claims 1
- 206010051696 Metastases to meninges Diseases 0.000 claims 1
- 238000010586 diagram Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 50
- 235000011472 cat’s claw Nutrition 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 42
- 244000003240 Caesalpinia gilliesii Species 0.000 description 40
- 235000014161 Caesalpinia gilliesii Nutrition 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 35
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 35
- 230000002776 aggregation Effects 0.000 description 27
- 238000004220 aggregation Methods 0.000 description 26
- 238000011534 incubation Methods 0.000 description 26
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 25
- 235000020204 cat's claw extract Nutrition 0.000 description 25
- 238000003556 assay Methods 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 238000001493 electron microscopy Methods 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 14
- 230000006378 damage Effects 0.000 description 14
- 231100000673 dose–response relationship Toxicity 0.000 description 14
- 230000003389 potentiating effect Effects 0.000 description 14
- 208000037259 Amyloid Plaque Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 238000002983 circular dichroism Methods 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- 229920000669 heparin Polymers 0.000 description 11
- 229960002897 heparin Drugs 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 208000000044 Amnesia Diseases 0.000 description 10
- -1 petunidin glycosides Chemical class 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 208000026139 Memory disease Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 8
- 230000035557 fibrillogenesis Effects 0.000 description 8
- 230000006984 memory degeneration Effects 0.000 description 8
- 208000023060 memory loss Diseases 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 238000001142 circular dichroism spectrum Methods 0.000 description 7
- 235000015872 dietary supplement Nutrition 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000003599 food sweetener Nutrition 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000003765 sweetening agent Substances 0.000 description 7
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 6
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001312569 Ribes nigrum Species 0.000 description 6
- 230000003941 amyloidogenesis Effects 0.000 description 6
- 230000001149 cognitive effect Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 206010019196 Head injury Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229940122777 Tau aggregation inhibitor Drugs 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000002887 neurotoxic effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000006403 short-term memory Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010059245 Angiopathy Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241001466042 Fulgoromorpha Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000020346 chamomile tea Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000002198 insoluble material Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 231100000189 neurotoxic Toxicity 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 210000000225 synapse Anatomy 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 241000283086 Equidae Species 0.000 description 3
- 101710163305 Fibril protein Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000029400 Inclusion myopathy Diseases 0.000 description 3
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 3
- 208000009829 Lewy Body Disease Diseases 0.000 description 3
- 201000002832 Lewy body dementia Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 241000607122 Uncaria tomentosa Species 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000003271 compound fluorescence assay Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010007509 Cardiac amyloidosis Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RKWHWFONKJEUEF-GQUPQBGVSA-O Cyanidin 3-O-glucoside Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 RKWHWFONKJEUEF-GQUPQBGVSA-O 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- OIZFQAFWYYKPMR-PEVLUNPASA-N Delphinidin 3-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C=1[C-](c2cc(O)c(O)c(O)c2)[O+]c2c(c(O)cc(O)c2)C=1 OIZFQAFWYYKPMR-PEVLUNPASA-N 0.000 description 2
- 206010063045 Effusion Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000007584 Prealbumin Human genes 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 108010048233 Procalcitonin Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 108010001122 alpha(2)-microglobulin Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 235000007336 cyanidin Nutrition 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000007242 delphinidin Nutrition 0.000 description 2
- XENHPQQLDPAYIJ-PEVLUNPASA-O delphinidin 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC(O)=C(O)C(O)=C1 XENHPQQLDPAYIJ-PEVLUNPASA-O 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 208000015756 familial Alzheimer disease Diseases 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000021245 head disease Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 231100000863 loss of memory Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 2
- 235000009584 malvidin Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- GXPTVXHTZZVLMQ-GCGJSEPQSA-N myrtillin Natural products O[C@H]1O[C@@H](OCC2=C(OC3=CC(=O)C=C(O)C3=C2)c4cc(O)c(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O GXPTVXHTZZVLMQ-GCGJSEPQSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 235000006251 pelargonidin Nutrition 0.000 description 2
- 235000006404 peonidin Nutrition 0.000 description 2
- 235000006384 petunidin Nutrition 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010067409 AN-1792 Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- 206010012426 Dermal cyst Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 241001091440 Grossulariaceae Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 235000003368 Ilex paraguariensis Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 241000282453 Ursus americanus Species 0.000 description 1
- 241001147416 Ursus maritimus Species 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036995 brain health Effects 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000021557 concentrated beverage Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 150000002116 epicatechin Chemical class 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- ZEKANFGSDXODPD-UHFFFAOYSA-N glyphosate-isopropylammonium Chemical compound CC(C)N.OC(=O)CNCP(O)(O)=O ZEKANFGSDXODPD-UHFFFAOYSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 102000057063 human MAPT Human genes 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000020331 mate tea Nutrition 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000001682 neurofibril Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 description 1
- XVFMGWDSJLBXDZ-UHFFFAOYSA-O pelargonidin Chemical compound C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 XVFMGWDSJLBXDZ-UHFFFAOYSA-O 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229930015721 peonidin Natural products 0.000 description 1
- XFDQJKDGGOEYPI-UHFFFAOYSA-O peonidin Chemical compound C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 XFDQJKDGGOEYPI-UHFFFAOYSA-O 0.000 description 1
- 229930015717 petunidin Natural products 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
この出願は、2018年12月12日に出願された米国仮出願62/778,875号の優先的利益を主張し、その全内容は参照により本明細書に組み込まれる。
技術分野
アルツハイマー病は、細胞外アミロイドプラークとしておよび脳血管壁内にアミロイドとして存在する、線維状形態の、ベータアミロイドタンパク質またはAβと呼ばれる39~43のアミノ酸ペプチドの蓄積を特徴とする。アルツハイマー病における線維性Aβアミロイド沈着は、患者に有害であると考えられており、最終的には、アルツハイマー病の特徴的な特徴である毒性および神経細胞死を引き起こす。蓄積された証拠は、アミロイド、より具体的には、アルツハイマー病の病因の主要な原因因子として、Aβフィブリルの形成、沈着、蓄積および/または持続を示唆している。さらに、アルツハイマー病に加えて、他の複数のアミロイド疾患は、ダウン症候群、これらに限定されないが、オランダ型の遺伝性脳出血などのコンゴ親和性血管障害を伴う障害、封入体筋炎、拳闘家認知症、脳β-アミロイド血管症、進行性核上麻痺に関連する認知症、皮質基底変性および軽度の認知障害に関連する認知症を含み、Aβフィブリルの形成、沈着、蓄積および持続を伴う。
アルツハイマー病の治療標的としてのアミロイド
高齢のヒトおよび動物の脳における「プラークおよびタングル」の蓄積
高齢のイヌおよびネコの脳における「プラーク」の蓄積
タウオパチーおよび「タングル」
「タングル」は外傷性脳損傷(TBI)、脳震盪、頭部外傷、および慢性外傷性脳症(CTE)において脳に蓄積する
いくつかの実施形態では、組成物は、アミロイドフィブリル形成を効果的に阻害し、アミロイドフィブリル成長を阻害し、かつ/または事前に形成されたアミロイドフィブリルの溶解および/または破壊を引き起こす。いくつかの実施形態では、組成物は、タウフィブリル形成を阻害し(初期から中期のタウオパチーの対象にとって重要である)、タウフィブリルの成長を阻害し(初期から中期のタウオパチーの対象にとって重要である)、かつ/または事前に形成されたタウフィブリルの溶解/破壊を引き起こす(後期タウオパチーにとって重要である)。いくつかの実施形態では、組成物は、ヒトにおいて脳の「プラークおよびタングル」を防止する、軽減させる、および/または除去するための認知および記憶サプリメントの開発に有用である。
定義
組成物
ブラック-カラント
キャッツクロー
ウーロン茶
使用
方法
投薬量
投与
配合物
実施例
組成物-成分の調製
実施例1:アルツハイマー病のAβフィブリルまたは凝集体の破壊/阻害
パートA:チオフラビンT蛍光光度計
パートB:コンゴーレッド
パートC:スライドベースのコンゴーレッド結合、チオフラビンSおよび電子顕微鏡
実施例2:フィブリル構造を含むβシートへのAβのIn Vitro変換の阻害/破壊
パートA:チオフラビンT蛍光光度計
パートB:コンゴーレッド
パートC:CD分光法
実施例3:タウ凝集阻害剤のin vitroスクリーニングのための組換えタウ反復ドメインの使用
実施例4:チオフラビンS蛍光測定スクリーニングによる新規タウ凝集阻害剤の同定
実施例5:円二色性(CD)分光法によるタンパク質二次構造の分析によるタウ凝集阻害の確認
実施例6:ネガティブ染色電子顕微鏡(EM)により決定されたタウタンパク質原線維形成の阻害および事前に形成されたタウフィブリルの脱凝集
実施例7:ブラックカラント抽出物の添加によるキャッツクロー/ウーロン茶抽出物の溶解
実施例8:認知および記憶の改善についてのin vivo試験
Claims (34)
- 治療的有効量のブラックカラント抽出物、ブラックカラント抽出物、およびウーロン茶抽出物を含む組成物。
- 前記ブラックカラント抽出物が、約10%~約35%w/wのプロアントシアニジン、アントシアニジン、アントシアニン、またはそれらの組み合わせを含む、請求項1に記載の組成物。
- 前記ブラックカラント抽出物が、約25%のプロアントシアニジン、アントシアニジン、アントシアニン、またはそれらの組み合わせを含む、請求項1または2に記載の組成物。
- 前記組成物が、約10mg~約100mgのブラックカラント抽出物を含む、請求項1~3のいずれか一項に記載の組成物。
- 前記組成物が、約1%~約10%w/wのブラックカラント抽出物を含む、請求項1~4のいずれか一項に記載の組成物。
- 前記組成物が、約100mg~約500mgのウンカリアトメントサ抽出物を含む、請求項1~5のいずれか一項に記載の組成物。
- 前記組成物が、約10%~約40%w/wのウンカリアトメントサ抽出物を含む、請求項1~6のいずれか一項に記載の組成物。
- 前記組成物が、約100mg~約500mgのウーロン茶抽出物を含む、請求項1~7のいずれか一項に記載の組成物。
- 前記組成物が、約10%~約40%w/wのウーロン茶抽出物を含む、請求項1~8のいずれか一項に記載の組成物。
- 前記組成物が、ピル、錠剤、カプレット、ソフトまたはハードゼラチンカプセル、ロゼンジ、サシェ、カシェ、ベジキャップ、液滴、エリキシル、懸濁液、エマルジョン、溶液、飲料調製物、冷たいまたは熱い茶系飲料、シロップ、茶バッグ、エアロゾル、坐剤、滅菌注射液、または滅菌包装粉末として配合される、請求項1~9のいずれか一項に記載の組成物。
- 前記組成物が、カプセルとして配合される、請求項1~10のいずれか一項に記載の組成物。
- 前記カプセルが、約200mg~約1000mgである、請求項11に記載の組成物。
- 前記組成物が、飲料調製物として配合される、請求項1~10のいずれか一項に記載の組成物。
- 前記飲料調製物が、飲料ショットである、請求項13に記載の組成物。
- 前記組成物が、ウンカリアトメントサ抽出物、ウーロン茶抽出物を含み、かつブラックカラント抽出物を含まない組成物よりも溶解性が高い、請求項1~14のいずれか一項に記載の組成物。
- 請求項1~12、または15のいずれか一項に記載の組成物を含むカプセル。
- 請求項1~10、13~15のいずれか一項に記載の組成物を含む飲料調製物。
- それを必要とする哺乳動物におけるアミロイドーシスの治療のための方法であって、請求項1~15のいずれか一項に記載の組成物をそれを必要とする前記哺乳動物に投与することを含む、方法。
- 前記アミロイドーシスは、アルツハイマー病、ダウン症候群、拳闘家認知症、認知機能障害症候群、イヌの認知機能障害、多系統萎縮症、封入体筋炎、オランダ型アミロイドーシスを伴う遺伝性脳出血、ニーマンピック病C型、脳アミロイド血管症、皮質基底変性に関連する認知症、2型糖尿病のアミロイドーシス、慢性炎症のアミロイドーシス、悪性腫瘍および家族性地中海熱のアミロイドーシス、多発性骨髄腫およびB細胞悪液質のアミロイドーシス、プリオン病のアミロイドーシス、クロイツフェルト・ヤコブ病、ゲルストマン・ストロスラー症候群、クールー、スクレイピー、手根管症候群に関連するアミロイドーシス、老人性心アミロイドーシス、家族性アミロイド性多発神経障害、または内分泌腫瘍に関連するアミロイドーシスである、請求項18に記載の方法。
- アミロイドフィブリルの形成、沈着、蓄積、または持続を処置する方法であって、請求項1~15のいずれか一項に記載の組成物で前記フィブリルを処置することを含む方法。
- ベータアミロイド含有プラークの形成、沈着、蓄積、または持続を処置する方法であって、請求項1~15のいずれか一項に記載の組成物で前記プラークを処置することを含む方法。
- それを必要とするヒトまたは哺乳動物におけるタウオパチーの治療のための方法であって、請求項1~15のいずれか一項に記載の組成物をそれを必要とする前記ヒトまたは前記哺乳動物に投与することを含む、方法。
- 前記タウオパチーは、アルツハイマー病、その封入体を伴う前頭側頭葉変性症(FLTD-タウ)、ピック病、進行性核上性麻痺、大脳皮質基底核変性症、嗜銀顆粒性認知症、プリオン病、グアムの筋萎縮性側索硬化症-パーキンソニズム-認知症複合体(リチコボディグ病とも呼ばれる)、パーキンソン病、タングル優位型認知症、ガングリオン、神経節膠腫、神経節細胞腫、髄膜腫症、亜急性硬化性全脳炎、鉛脳症、結節性硬化症、ハレルフォルデン‐スパッツ病、リポフスチン症、外傷性脳損傷(TBI)、慢性外傷性脳症(CTE)、拳闘家認知症、脳震盪、頭部への1回または繰り返しの打撃、または心的外傷後ストレス障害である、請求項22に記載の方法。
- タウタンパク質含有タングルの形成、沈着、蓄積、または持続を処置する方法であって、請求項1~15のいずれか一項に記載の組成物で前記タングルを処置することを含む方法。
- それを必要とする対象の脳中のプラークを阻害する、防止する、低減させる、または処置するための方法であって、請求項1~15のいずれか一項に記載の組成物を前記対象に投与することを含む、方法。
- それを必要とする対象における認知能力を改善するかつ/または認知低下を遅らせるための方法であって、対象におけるベータアミロイドタンパク質プラークまたはフィブリルの形成、沈着、蓄積または持続を低減するために請求項1~15のいずれか一項に記載の組成物を前記対象に投与することを含む、方法。
- 前記対象は、アミロイド疾患罹患患者である、請求項26に記載の方法。
- それを必要とする対象における学習、記憶、認知、集中および/または専心性を改善するための方法であって、請求項1~15のいずれか一項に記載の組成物を前記対象に投与することを含む、方法。
- 前記対象は、加齢関連性記憶障害(AAMI)、軽度認知障害(MCI)またはアルツハイマー病の患者である、請求項28に記載の方法。
- それを必要とする対象の脳中のタングルを阻害する、防止する、低減させる、または処置するための方法であって、請求項1~15のいずれか一項に記載の組成物を前記対象に投与することを含む、方法。
- 前記対象は、単一または複数の脳震盪、外傷性脳損傷(TBI)、頭部への打撃、慢性外傷性脳症(CTE)、心的外傷後ストレス障害、脳老化、軽度認知障害またはアルツハイマー病を経験した患者である、請求項30に記載の方法。
- 高齢のイヌまたはネコの脳中のプラークおよびタングルを予防する、低減するまたは処置するための方法であって、請求項1~15のいずれか一項に記載の組成物で前記プラークおよびタングルを処置することを含む、方法。
- 脳のプラークおよびタングルの形成、沈着、蓄積および/または持続に罹患している高齢のイヌまたはネコにおける認知能力を改善するおよび/または認知低下を遅らせるための方法であって、請求項1~15のいずれか一項に記載の組成物を前記高齢のイヌまたはネコに投与することを含む、方法。
- 脳中のタングルを阻害することまたは減少させることにより対象における運動能力を改善するための方法であって、請求項1~15のいずれか一項に記載の組成物を前記対象に投与することを含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862778875P | 2018-12-12 | 2018-12-12 | |
US62/778,875 | 2018-12-12 | ||
PCT/US2019/063455 WO2020123152A1 (en) | 2018-12-12 | 2019-11-26 | Compositions and methods for the treatment of "plaques and tangles" in humans and animals |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022512372A true JP2022512372A (ja) | 2022-02-03 |
JPWO2020123152A5 JPWO2020123152A5 (ja) | 2022-12-02 |
Family
ID=71071419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021533339A Pending JP2022512372A (ja) | 2018-12-12 | 2019-11-26 | ヒトおよび動物における「プラークおよびタングル」の処置のための組成物および方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US11491201B2 (ja) |
EP (1) | EP3893907A4 (ja) |
JP (1) | JP2022512372A (ja) |
CN (1) | CN113301906A (ja) |
AU (1) | AU2019397260A1 (ja) |
CA (1) | CA3122687A1 (ja) |
CO (1) | CO2021008890A2 (ja) |
DO (1) | DOP2021000110A (ja) |
MX (1) | MX2021006987A (ja) |
PH (1) | PH12021551342A1 (ja) |
SG (1) | SG11202106222YA (ja) |
WO (1) | WO2020123152A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007530607A (ja) * | 2004-03-30 | 2007-11-01 | ユニリーバー・ナームローゼ・ベンノートシヤープ | ビタミンおよびフラボノイドを含むスキンライトニング組成物 |
JP2018513838A (ja) * | 2015-02-27 | 2018-05-31 | コグニティヴ クラリティ インコーポレイテッド | ヒトおよび動物における「プラークおよびもつれ」の処置のための組成物と方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5683698A (en) * | 1996-08-02 | 1997-11-04 | New England Deaconess Hospital | Formulation for alleviating symptoms associated with arthritis |
US6264994B1 (en) | 1997-05-15 | 2001-07-24 | University Of Washington | Compositions for treating alzheimer's disease and other amyloidoses |
CA2289531C (en) | 1997-05-15 | 2009-09-29 | University Of Washington | Composition and methods for treating alzheimer's disease and other amyloidoses |
US6346280B1 (en) | 1997-05-15 | 2002-02-12 | University Of Washington | Composition and methods for inhibiting the formation of brain amyloid deposits |
CA2323090C (en) | 1998-03-13 | 2009-08-04 | University Of Washington | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases |
JP2003171298A (ja) | 2001-12-11 | 2003-06-17 | Nonogawa Shoji Kk | 抗アレルギー剤 |
US8034387B2 (en) | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
US20070190075A1 (en) | 2003-10-09 | 2007-08-16 | Advangen, Inc. C/O National Institute Of Advance Science And Tech | Hair growth stimulant composition |
JP4321769B2 (ja) | 2004-04-13 | 2009-08-26 | Towa Corporation 株式会社 | 抗ヒスタミン用組成物、アレルギ性鼻炎の予防および治療用組成物、花粉症の予防および治療用組成物およびじんま疹治療用組成物 |
JP4954552B2 (ja) | 2006-01-07 | 2012-06-20 | 日本メナード化粧品株式会社 | 抗アレルギー剤 |
JP2007230977A (ja) | 2006-03-03 | 2007-09-13 | Naris Cosmetics Co Ltd | 顆粒球・マクロファージコロニー刺激因子(gm−csf)産生抑制剤ii |
JP2007277163A (ja) | 2006-04-06 | 2007-10-25 | Uha Mikakuto Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
TW200812637A (en) | 2006-09-15 | 2008-03-16 | jun-er Wang | Vegetable composition for cleaning oral cavity |
JP2010013423A (ja) | 2008-07-07 | 2010-01-21 | Lion Corp | ジペプチジルペプチダーゼ−iv阻害剤 |
JP5688606B2 (ja) * | 2012-02-17 | 2015-03-25 | 株式会社シェフコ | 機能性原料を含有する水素含有飲料の製造方法 |
KR20190008300A (ko) * | 2016-05-17 | 2019-01-23 | 알파젠 엔지 리미티드 | L-테아닌, 프로안토시아니딘 및 카테킨을 포함하는 조성물 및 그 용도 |
WO2018022828A1 (en) | 2016-07-29 | 2018-02-01 | The Procter & Gamble Company | Catalysts for making acrylic acid from lactic acid or its derivatives in liquid phase |
-
2019
- 2019-11-26 SG SG11202106222YA patent/SG11202106222YA/en unknown
- 2019-11-26 MX MX2021006987A patent/MX2021006987A/es unknown
- 2019-11-26 EP EP19896545.1A patent/EP3893907A4/en active Pending
- 2019-11-26 US US16/697,171 patent/US11491201B2/en active Active
- 2019-11-26 WO PCT/US2019/063455 patent/WO2020123152A1/en unknown
- 2019-11-26 AU AU2019397260A patent/AU2019397260A1/en active Pending
- 2019-11-26 CN CN201980089055.5A patent/CN113301906A/zh active Pending
- 2019-11-26 JP JP2021533339A patent/JP2022512372A/ja active Pending
- 2019-11-26 CA CA3122687A patent/CA3122687A1/en active Pending
-
2021
- 2021-06-08 PH PH12021551342A patent/PH12021551342A1/en unknown
- 2021-06-10 DO DO2021000110A patent/DOP2021000110A/es unknown
- 2021-07-06 CO CONC2021/0008890A patent/CO2021008890A2/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007530607A (ja) * | 2004-03-30 | 2007-11-01 | ユニリーバー・ナームローゼ・ベンノートシヤープ | ビタミンおよびフラボノイドを含むスキンライトニング組成物 |
JP2018513838A (ja) * | 2015-02-27 | 2018-05-31 | コグニティヴ クラリティ インコーポレイテッド | ヒトおよび動物における「プラークおよびもつれ」の処置のための組成物と方法 |
Non-Patent Citations (3)
Title |
---|
CIRCULATION, vol. Vol.125, suppl_10, JPN6023040434, 2012, pages 356, ISSN: 0005165668 * |
JOURNAL OD ALZHEIMER'S DISEASE, vol. 6, JPN6023040435, 2004, pages 403 - 411, ISSN: 0005165669 * |
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, vol. 24, JPN6023040433, 2013, pages 360 - 370, ISSN: 0005165667 * |
Also Published As
Publication number | Publication date |
---|---|
CO2021008890A2 (es) | 2021-07-30 |
CA3122687A1 (en) | 2020-06-18 |
US11491201B2 (en) | 2022-11-08 |
AU2019397260A1 (en) | 2021-06-24 |
MX2021006987A (es) | 2021-08-11 |
EP3893907A1 (en) | 2021-10-20 |
US20200188467A1 (en) | 2020-06-18 |
WO2020123152A1 (en) | 2020-06-18 |
PH12021551342A1 (en) | 2021-12-13 |
DOP2021000110A (ja) | 2021-12-15 |
SG11202106222YA (en) | 2021-07-29 |
EP3893907A4 (en) | 2022-11-30 |
CN113301906A (zh) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10166267B1 (en) | Multi-component formulations for the treatment of cognitive decline including Alzheimer's disease | |
Lee et al. | Inhibitory effect of ethanol extract of Magnolia officinalis on memory impairment and Amyloidogenesis in a transgenic mouse model of Alzheimer's disease via regulating β‐secretase activity | |
US11376300B2 (en) | Compositions and methods for the treatment of plaques and tangles in humans and animals | |
Liu et al. | Mulberry fruit extract alleviates cognitive impairment by promoting the clearance of amyloid-β and inhibiting neuroinflammation in Alzheimer’s disease mice | |
CN102083444A (zh) | 用于预防和治疗神经退行性疾病的方法 | |
JP2011503237A (ja) | Scutellariabarbatad.donの精製抽出物を作製するためのプロセス | |
Khan et al. | Preclinical development of gastro-protective botanical candidate from Woodfordia fruticosa (Linn.) Kurz: Chemical standardization, efficacy, pharmacokinetics and safety pharmacology | |
WO2011158247A1 (en) | A novel herbal formulation for the prevention and management of type-2 diabetes mellitus and vascular complications associated with diabetes | |
KR20200116054A (ko) | 봉독 추출물을 유효성분으로 함유하는 신경염증 질환 예방 또는 치료용 조성물 | |
JP2022512372A (ja) | ヒトおよび動物における「プラークおよびタングル」の処置のための組成物および方法 | |
US20070154580A1 (en) | Antiviral Morinda Citrifolia L. Based Formulations and Methods of Administration | |
EP3949974A1 (en) | Composition for preventing or treating neuroinflammatory disorders, comprising bee venom extract as active ingredient | |
Al Damen et al. | Effects on cognition of berry, pomegranate, grape and biophenols: a general review | |
Al-Dujaili | Effects of Berry, Pomegranate, Grape and their Biophenols on Cognitive Function: A General Review | |
Sil et al. | Protective effects of black tea-TV 25 on the cognitive impairments and some peripheral immune responses in intracerebroventricular colchicine injected rats | |
Kelly | Potential effects of blueberries on markers of neurodegenerative disease | |
Kiruthika | Preclinical validation of the possible mechanisms of Anti-Hypertensive, Diuretic and Anti-oxidant Activity of Venthamaraiyathi Chooranam in Rodents | |
Sumithra | Preclinical Evaluation of the Possible Mechanisms of Anti-Hypertensive, Diuretic, Anti-oxidant Activities of Munthirikai Chooranam in Rodents | |
KR20220056390A (ko) | 모과 추출물을 함유하는 전립선비대증 개선용 조성물 | |
Sayyed | In-Vitro Assessment of Cholinesterase Inhibitory and Antioxidant Activities of Plant Pterocarpus santalinus | |
KR101361785B1 (ko) | 블루베리 잎 추출물을 포함하는 퇴행성 뇌신경질환의 예방 또는 치료용 약학적 조성물 | |
Wang et al. | Yishen Huazhuo Decoction Regulates Microglial Polarization to Reduce Neuroinflammation at the Early Stage of Alzheimer's Disease Through TREM2 | |
Nasimolo | Anti-inflammatory Potential Of The Coral Tree (erythrina Abyssinica): Histological And Immunohistochemical Evidence In Chronic Trypanosomiasis Mouse Model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221124 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240301 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240625 |